Drs. Jeffrey Heier and Peter Kaiser of Ocular Therapeutix join to discuss the SOL-1 trial results investigating a novel tyrosine kinase inhibitor for wet age-related macular degeneration. Conflicts of Interest: Dr. Sridhar has consulted on an advisory board in the past 24 months for Ocular Therapeutix. Dr. Heier and Dr. Kaiser are employed by Ocular Therapeutix.